Showing 1196 results
- Media Release /Despite major advances in modern medicine, universal access to healthcare remains the largest unmet medical need Building on the inaugural Sandoz HACk, this year's competition expands to seek…
- Media Release /Clinical and pre-clinical stage programs focused on addressing growing need for new treatments against drug resistant Gram-negative bacteria Agreement is part of Novartis strategy to…
- Media Release /A panel of independent ophthalmologists and optometrists selected five winners out of more than 100 entries from 34 countries The 2018 grants support initiatives ranging from training teachers…
- Media Release /In the Phase III RAINBOW study, despite marginally missing statistical significance for the primary endpoint of demonstrating superiority of Lucentis® to laser surgery, Lucentis was shown to be…
- Media Release /Pre-specified analysis provides insight into maintenance treatment effectiveness with like-for-like comparison of brolucizumab versus aflibercept over entire week 36 to 48 treatment period …
- Media Release /US FDA has classified drug shortage status as resolved1 Novartis capacity to produce Pluvicto will continue to grow with anticipated expansions to the manufacturing network in the US and globally…
- Media Release /Positive opinion is based on comprehensive data confirming that Sandoz biosimilar pegfilgrastim matches the reference medicine in terms of safety, efficacy and qualitySandoz seeks approval in the…
- Media Release /Children and adolescents with multiple sclerosis (MS) experience more frequent and often more severe relapses than adults with the disease, hindering their development and ability to take part in…
- Media Release /If approved in expected timeframe, Luxturna* (voretigene neparvovec) will be first and only gene therapy available in EU to treat a rare inherited retinal disease Children and adults…
- Key Release /Ad hoc announcement pursuant to Art. 53 LR Transformation into a “pure-play” innovative medicines business is complete, with the spin-off of Sandoz; commentary below is on continuing…
Pagination
- ‹ Previous page
- 1
- …
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- …
- 120
- › Next page